Early detection, tracking of progression and differential diagnosis of Alzheimer’s and dementia in general to help find a cure.

Oxford Brain Diagnostics Ltd is a spinout company from the University of Oxford developing diagnostics based on changes in the brain at the cellular level, with focus on diagnosis of Alzheimer’s disease – early detection, progression tracking, and supporting differential diagnosis using MRI brain scan data.

The patent-protected ‘Cortical Disarray Measurement’ (CDM) is a software-based technology that is designed to identify changes in the brain at a cellular level, to enable sensitive and accurate assessment of the neurodegeneration associated with Alzheimer’s disease and other dementias. Oxford Brain Diagnostics’ CDM software device will support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s disease. The CDM software device was awarded Breakthrough Device designation by the FDA in August 2020.

We are looking for partners to use this diagnostic tool to develop therapies and cures against dementia and help the many affected patients and their families.